[Therapeutic difference by TAE between HCC with HCV-Ab and HBV-Ag].
Transarterial infusion therapy using adriamycin-Lipiodol emulsion (TAE) was used for 30 patients of HCC with HCV-Ab and 20 patients with HBV-Ag. We compared the tumor effect and prognosis in terms of several clinico-pathological factors. The response rate (PR+MR) after TAE was 43% in HCC patients with HCV-Ab and 30% in those with HBV-Ag. One-year survival rate was 89% in HCC patients with HCV-Ab and 58% in HCC patients with HBV-Ag. Thus, there was a significant difference between the two groups. No definite reasons between two groups influencing tumor effect and prognosis is obviously revealed except for portal vein invasion.
Ninomiya
E
E
Dept. of Internal Medicine, Cancer Institute Hospital.
Ohhashi
K
K
Murakami
Y
Y
Yamada
M
M
Takano
K
K
Nagahama
T
T
Ogawa
M
M
Horikoshi
N
N
Inoue
K
K
D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D004621:Embolization, Therapeutic; D004655:Emulsions; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006499:Hepatic Artery; D006508:Hepatitis Antibodies / Q000032:analysis*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male
D004655:Emulsions; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D007459:Iodized Oil; D004317:Doxorubicin